Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-113 (**Cancelled**)

114. (**Previously Presented**) An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a K179E SNP.

115. (**Previously Presented**) A composition comprising the polypeptide of claim 114 and at least one excipient.

116. (**Previously Presented**) The composition of claim 115, wherein said excipeint is a pharmaceutically acceptable excipient.

117. (**Previously Presented**) The composition of 115, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

118. (**Previously Presented**) A pharmaceutical composition comprising the polypeptide of claim 114 and a pharmaceutically acceptable excipient.

119. (**Previously Presented**) The pharmaceutical composition of 118, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

120. (**Previously Presented**) An isolated polypeptide comprising an amino acid sequence at least 95% identical to

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;

wherein said sequence comprises a K179E SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.

121. (**Previously Presented**) The polypeptide of claim 120, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.

122. (**Previously Presented**) The polypeptide of claim 120, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.

123. (**Previously Presented**) The polypeptide of claim 120, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

124. (**Previously Presented**) The polypeptide of claim 120, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

125. (**Previously Presented**) A composition comprising the polypeptide of claim 120 and at least one excipient.

126. (**Previously Presented**) The composition of claim 125, wherein said excipeint is a pharmaceutically acceptable excipient.

127. (**Previously Presented**) The composition of 125, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

128. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 120 and a pharmaceutically acceptable excipient.

129. **(Previously Presented)** The pharmaceutical composition of 128, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

130. **(Previously Presented)** An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q102K SNP.

131. **(Previously Presented)** A composition comprising the polypeptide of claim 130 and at least one excipient.

132. **(Previously Presented)** The composition of claim 131, wherein said excipeint is a pharmaceutically acceptable excipient.

133. **(Previously Presented)** The composition of 131, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

134. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 130 and a pharmaceutically acceptable excipient.

135. **(Previously Presented)** The pharmaceutical composition of 134, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

136. (**Previously Presented**) An isolated polypeptide comprising an amino acid sequence at least 95% identical to

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q102K SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.

137. (**Previously Presented**) The polypeptide of claim 136, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.

138. (**Previously Presented**) The polypeptide of claim 136, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.

139. (**Previously Presented**) The polypeptide of claim 136, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

140. (**Previously Presented**) The polypeptide of claim 136, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

141. (**Previously Presented**) A composition comprising the polypeptide of claim 136 and at least one excipient.

142. (**Previously Presented**) The composition of claim 141, wherein said excipeint is a pharmaceutically acceptable excipient.

143. (**Previously Presented**) The composition of 141, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

144. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 136 and a pharmaceutically acceptable excipient.

145. **(Previously Presented)** The pharmaceutical composition of 144, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

146. **(Previously Presented)** An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q114H SNP.

147. **(Previously Presented)** A composition comprising the polypeptide of claim 146 and at least one excipient.

148. **(Previously Presented)** The composition of claim 147, wherein said excipeint is a pharmaceutically acceptable excipient.

149. **(Previously Presented)** The composition of 147, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

150. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 146 and a pharmaceutically acceptable excipient.

151. **(Previously Presented)** The pharmaceutical composition of 150, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

152. (**Previously Presented**) An isolated polypeptide comprising an amino acid sequence at least 95% identical to

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;

wherein said sequence comprises a Q114H SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.

153. (**Previously Presented**) The polypeptide of claim 152, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.

154. (**Previously Presented**) The polypeptide of claim 152, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.

155. (**Previously Presented**) The polypeptide of claim 152, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

156. (**Previously Presented**) The polypeptide of claim 152, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

157. (**Previously Presented**) A composition comprising the polypeptide of claim 152 and at least one excipient.

158. (**Previously Presented**) The composition of claim 157, wherein said excipeint is a pharmaceutically acceptable excipient.

159. (**Previously Presented**) The composition of 157, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

160. (**Previously Presented**) A pharmaceutical composition comprising the polypeptide of claim 152 and a pharmaceutically acceptable excipient.

161. (**Previously Presented**) The pharmaceutical composition of 160, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

162. (**Previously Presented**) An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a V127D SNP.

163. (**Previously Presented**) A composition comprising the polypeptide of claim 162 and at least one excipient.

164. (**Previously Presented**) The composition of claim 163, wherein said excipeint is a pharmaceutically acceptable excipient.

165. (**Previously Presented**) The composition of 163, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

166. (**Previously Presented**) A pharmaceutical composition comprising the polypeptide of claim 162 and a pharmaceutically acceptable excipient.

167. (**Previously Presented**) The pharmaceutical composition of 166, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

168. **(Previously Presented)** An isolated polypeptide comprising an amino acid sequence at least 95% identical to

a) the amino acid sequence of SEQ ID NO. 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a V127D SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.

169. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.

170. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.

171. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

172. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

173. **(Previously Presented)** A composition comprising the polypeptide of claim 168 and at least one excipient.

174. **(Previously Presented)** The composition of claim 173, wherein said excipeint is a pharmaceutically acceptable excipient.

175. **(Previously Presented)** The composition of 173, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

176. (**Previously Presented**) A pharmaceutical composition comprising the polypeptide of claim 168 and a pharmaceutically acceptable excipient.

177. (**Previously Presented**) The pharmaceutical composition of 176, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

Claims 178-193 (**Cancelled**)